


PHARMACEUTICAL 2023

Blueprint Medicines Corp Rank 270 of 446







PHARMACEUTICAL 2023

Blueprint Medicines Corp Rank 270 of 446



The relative strengths and weaknesses of Blueprint Medicines Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Blueprint Medicines Corp compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 24% points. The greatest weakness of Blueprint Medicines Corp is the variable Other Liabilities, reducing the Economic Capital Ratio by 84% points.

The company's Economic Capital Ratio, given in the ranking table, is 30%, being 13% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	1,046,651
Cost of Goods Sold	17,813
Intangible Assets	0
Liabilities, Current	183,234
Liabilities, Non-Current	116,714
Other Assets	269,907
Other Compr. Net Income	-6,310
Other Expenses	14,184
Other Liabilities	535,277
Other Net Income	-14,763
Other Revenues	204,036
Property and Equipment	33,344
Research and Development	477,419
Selling, General and Administrative Expense	237,374

Output Variable	Value in 1000 USD
Assets	1,349,902
Liabilities	835,225
Expenses	746,790
Revenues	204,036
Stockholders Equity	514,677
Net Income	-557,517
Comprehensive Net Income	-560,672
Economic Capital Ratio	30%

